- Home
- GRRR vs PRTA Comparison
GRRR vs PRTA Comparison
Compare GRRR & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- PRTA
- Stock Information
- Founded
- GRRR 2001
- PRTA 2012
- Country
- GRRR United Kingdom
- PRTA Ireland
- Employees
- GRRR N/A
- PRTA N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- PRTA Health Care
- Exchange
- GRRR Nasdaq
- PRTA Nasdaq
- Market Cap
- GRRR 417.6M
- PRTA 351.5M
- IPO Year
- GRRR N/A
- PRTA N/A
- Fundamental
- Price
- GRRR $15.98
- PRTA $6.81
- Analyst Decision
- GRRR Buy
- PRTA Buy
- Analyst Count
- GRRR 1
- PRTA 9
- Target Price
- GRRR $18.00
- PRTA $27.67
- AVG Volume (30 Days)
- GRRR 2.1M
- PRTA 808.3K
- Earning Date
- GRRR 09-29-2025
- PRTA 08-04-2025
- Dividend Yield
- GRRR N/A
- PRTA N/A
- EPS Growth
- GRRR N/A
- PRTA N/A
- EPS
- GRRR N/A
- PRTA N/A
- Revenue
- GRRR $84,196,961.00
- PRTA $137,935,000.00
- Revenue This Year
- GRRR $38.13
- PRTA N/A
- Revenue Next Year
- GRRR $28.55
- PRTA $122.46
- P/E Ratio
- GRRR N/A
- PRTA N/A
- Revenue Growth
- GRRR 19.91
- PRTA 54.55
- 52 Week Low
- GRRR $2.09
- PRTA $4.32
- 52 Week High
- GRRR $44.15
- PRTA $23.66
- Technical
- Relative Strength Index (RSI)
- GRRR 36.56
- PRTA 59.66
- Support Level
- GRRR $17.48
- PRTA $6.74
- Resistance Level
- GRRR $17.15
- PRTA $7.33
- Average True Range (ATR)
- GRRR 0.95
- PRTA 0.32
- MACD
- GRRR -0.37
- PRTA 0.03
- Stochastic Oscillator
- GRRR 8.29
- PRTA 55.56
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.